no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
1 |
Editorial Board
|
|
|
2013 |
45 |
S5 |
p. i- 1 p. |
article |
2 |
HCV burden in Europe and the possible impact of current treatment
|
Mathurin, Philippe |
|
2013 |
45 |
S5 |
p. S314-S317 4 p. |
article |
3 |
Management of anaemia and other treatment complications
|
Hézode, Christophe |
|
2013 |
45 |
S5 |
p. S337-S342 6 p. |
article |
4 |
Optimizing DAA management in daily practice
|
Serfaty, Lawrence |
|
2013 |
45 |
S5 |
p. S318-S322 5 p. |
article |
5 |
Optimizing treatment in HIV/HCV coinfection
|
Puoti, Massimo |
|
2013 |
45 |
S5 |
p. S355-S362 8 p. |
article |
6 |
Practical insights into enhanced management of patients with HCV infection with direct antiviral agents
|
Colombo, Massimo |
|
2013 |
45 |
S5 |
p. S313- 1 p. |
article |
7 |
Preparing the patient for success: Treat or wait?
|
Buti, Maria |
|
2013 |
45 |
S5 |
p. S332-S336 5 p. |
article |
8 |
Safety of direct antiviral agents in real life
|
D’Ambrosio, Roberta |
|
2013 |
45 |
S5 |
p. S363-S366 4 p. |
article |
9 |
The importance of drug–drug interactions in the DAA era
|
Back, David |
|
2013 |
45 |
S5 |
p. S343-S348 6 p. |
article |
10 |
The importance of HCV RNA measurement for tailoring treatment duration
|
Peiffer, Kai-Henrik |
|
2013 |
45 |
S5 |
p. S323-S331 9 p. |
article |
11 |
Treatment of chronic hepatitis C virus infection after liver transplantation
|
Agarwal, Kosh |
|
2013 |
45 |
S5 |
p. S349-S354 6 p. |
article |